

Formycon

Pharma & biotech

11 May 2018

Lucentis biosimilar scores Phase III success

Formycon has announced that its Lucentis biosimilar FYB201 showed comparable efficacy with branded Lucentis in a global Phase III study in nAMD. With positive data in hand, the launch of FYB201 remains on track for 2020 (US) and 2022 (EU), ahead of most competitors. Formycon has also signed a JV (24.9% stake) with Aristo to develop its Stelara biosimilar FYB202 for approval. Lastly, Eylea biosimilar FYB203 and undisclosed FYB205 are advancing in preclinical studies. End-2017 cash was €15.5m.

Lucentis biosimilar on track for global launch

FYB201 has met the primary endpoint of comparable change in visual acuity at eight weeks compared to Lucentis in the global COLUMBUS-AMD Phase III study. FYB201 is partnered with Bioeq IP in a deal worth over €100m. Bioeq IP, which holds exclusive global marketing rights to FYB201, is seeking marketing partners and aims to launch the product in mid-2020 (US) and 2022 (EU) on patent expirations. Sales of Lucentis were \$3.3bn in 2017. Pfenex, Xbrane and Intas are at an earlier stage of development. Samsung Bioepis has an ongoing Phase III, and is the closest rival.

Joint venture with Aristo for Stelara biosimilar

The 24.9/75.1% JV reflects each company's share of expenses and eventual revenues from Stelara biosimilar. It will run a pilot study before embarking on full clinical development until registration of FYB202. We expect the JV to license the asset for commercialisation. Stelara is indicated for psoriasis and Crohn's disease. Patent protection extends to 2023 (US) and 2024 (EU). 2017 sales were \$4bn.

Eylea biosimilar candidate approaching the clinic

Formycon and Santo are advancing Eylea biosimilar FYB203 through preclinical studies with the aim of entering clinical trials for nAMD (timeline not provided). The deal involves an upfront payment of single-digit million euros and ongoing payments for its product development activities up to regulatory approval; sales revenue may reach double digits pa. Eylea patents expire in 2023 (US) and 2025 (EU). 2017 revenue was \$6.3bn. Mylan and Momenta Pharmaceuticals plan to start a pivotal trial of their Eylea biosimilar in H118. Alteogen's ALT-L9 and Coherus's CHS-2020 are preclinical-stage biosimilars of Eylea.

Valuation reflects progression

Formycon's market cap is c €362m and enterprise value (EV) is c €347m. The investment case rests on pipeline progression and additional partnerships.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/16	19.53	(4.06)	(0.46)	0.0	N/A	N/A
12/17	29.43	(1.58)	(0.17)	0.0	N/A	N/A
12/18e	28.65	(0.25)	(0.02)	0.0	N/A	N/A
12/19e	27.10	(3.00)	(0.32)	0.0	N/A	N/A

Source: Bloomberg consensus estimates, Formycon data

Price €38.8

Market cap €362m

Share price graph



Share details

Code	FYB
Listing	Deutsche Börse Scale
Shares in issue	9.34m
Cash at end December 2017	€15.5m

Business description

Formycon is a biotechnology company focused on biosimilars. The lead product is FYB201, a Lucentis biosimilar in Phase III; FYB203 is an Eylea biosimilar in the preclinical stage. They are both partnered. FYB202, a biosimilar candidate of Stelara, is being developed in a JV with Aristo Pharma. It also has an undisclosed biosimilar, FYB205, unpartnered.

Bull

- Leading biosimilars company addressing an \$11-12bn market.
- Two partnered products in multi-million euro deals.
- Potential first-to-market advantage for FYB201.

Bear

- No EMA guidance for intraocular biosimilars.
- US biosimilar market still immature.
- Lucentis market declined in 2014-17.

Analysts

Juan Pedro Serrate	+44 (0)20 3681 2534
Jonas Peciulis	+44 (0)20 3077 5728

healthcare@edisongroup.com
[Edison profile page](#)

Edison Investment Research provides qualitative research coverage on companies in the Deutsche Börse Scale segment in accordance with section 36 subsection 3 of the General Terms and Conditions of Deutsche Börse AG for the Regulated Unofficial Market (Freiverkehr) on Frankfurter Wertpapierbörse (as of 1 March 2017). Two to three research reports will be produced per year. Research reports do not contain Edison analyst financial forecasts.

Financials: FY17 results

Revenues increased to €29.43m from €19.53m in 2016. This exceeded the company's guidance of €25m, mainly due to payments received from Aristo Pharma associated with the JV. Sales come mainly from the partnering agreements for FYB201 and FYB203. Formycon has guided for the same revenue levels in 2018 as 2017. We believe that revenues will continue to be dependent on current and future potential partnerships, which may involve FYB202.

Total expenses increased to €31m in 2017 from €23.7m in 2016, mostly due to increased personnel expenses (the number of employees increased from 70 to 83) and third-party services (from €8.47m to €18.7m), which relate to the advancement of its development programmes. EBITDA loss was €0.75m vs a loss of €3.37m in 2016 and the net loss was €1.58m vs €4.07m in 2016. These improvements are due to the increase in revenues.

Cash burn in 2017 was €4.68m vs €6.40m in 2016. Formycon raised €6m in July 2017 in a private placement mainly intended to advance FYB202. Cash and equivalents were €15.48m at end December 2017. Short-term receivables were c €10.6m. Formycon has no financial debt.

Exhibit 1: Financial summary					
Year end 31 December (€m)	2013	2014	2015	2016	2017
Income statement					
Revenue	0.40	12.70	16.9	19.53	29.43
Profit before tax (as reported)	(7.77)	0.87	0.60	(4.06)	(1.58)
Net income (as reported)	(7.77)	0.87	0.60	(4.07)	(1.58)
EPS (as reported)* (€)	(0.90)	0.10	0.06	(0.46)	(0.17)
Dividend per share (€)	0.00	0.00	0.00	0.00	0.00
Balance sheet					
Total non-current assets	6.25	4.03	3.74	4.40	4.11
Total current assets	10.90	12.88	23.41	20.80	26.72
Total assets	17.20	16.91	27.15	25.19	30.83
Total current liabilities	(2.70)	(3.26)	(1.61)	(3.58)	(4.01)
Total non-current liabilities	(0.50)	(0.53)	(0.66)	(0.72)	(1.27)
Total liabilities	(3.19)	(3.80)	(2.28)	(4.30)	(5.28)
Net assets	13.90	13.11	24.87	20.89	25.54
Shareholders' equity	13.90	13.11	24.87	20.89	25.54
Cash flow statement					
Net cash from operating activities	(16.62)	(0.03)	0.52	(5.04)	(4.20)
Net cash from investing activities	(0.04)	(0.57)	(0.60)	(1.35)	(0.51)
Net cash from financing activities	17.43	(0.01)	11.15	0.06	(6.20)
Net cash flow	0.68	(0.61)	11.07	(6.33)	1.51
Cash & cash equivalent end of year	0.90	0.29	20.30	13.97	15.48

Source: Formycon accounts, *Bloomberg

Valuation

Formycon's market cap is c €362m and enterprise value (EV) is c €347m. The share price has risen 15% year to date. The company has two assets (FYB201 and FYB203) targeting the entire biologics neovascular age-related macular degeneration (nAMD) market, comprising Lucentis and Eylea. Lucentis had sales of \$3.3bn in 2017, projected to reach \$3bn in 2020 according to EvaluatePharma's (EP) consensus forecast. Eylea's 2017 sales were \$6.3bn, expected to reach \$7.5bn in 2020 (source: EP). Assuming a 50% discount and 50% penetration for biosimilars, the target market for Formycon's nAMD products would be \$2.62bn, on which Formycon may receive royalties and milestones. Stelara had sales of \$4bn in 2017 and EP's consensus forecast is c \$6.67bn in 2023 when the patent expires. Using the same assumptions, the potential market for a Stelara biosimilar (eg FYB202) would be c \$1.67bn. The company plans to partner the undisclosed biosimilar FYB205 in the future. We also believe that the valuation reflects the background,

expertise and successful track record of the company's management. The investment case rests on the progression of the pipeline in the clinic and additional partnerships.

In our view, the closest peers are Pfenex (market cap \$150m; EV \$75.5m), Xbrane (market cap SEK371.7m; EV SEK362m), Coherus BioSciences (market cap \$938m; EV \$741m) and Samsung Bioepis (private). However, these companies are at different stages of development with several other assets in the pipeline, which complicates any peer group comparison. Furthermore, relative valuation metrics, such as P/E, are difficult to assess, given the early-stage and often loss-making nature of these development companies.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Any information, data, analysis and opinions contained in this report do not constitute investment advice by Deutsche Börse AG or the Frankfurter Wertpapierbörse. Any investment decision should be solely based on a securities offering document or another document containing all information required to make such an investment decision, including risk factors.

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Deutsche Börse AG and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2018. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.